Overview
Beyond the Procedure: Evolving the Current Standard of Care for Patients with PAD
Stopping Amputation Post-revascularization: Novel Data in Mitigation of Thrombosis Risk
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In three fast-paced modules, a multispecialty panel of cardiology, radiology, and vascular surgery experts provide perspectives on preventing adverse limb events in patients undergoing revascularization. Vascular medicine expert Dr. Anahita Dua moderates these brief discussions and case presentations with a focus on the latest clinical trial data and implications for patient care.
This activity is intended for vascular surgeons, interventional cardiologists, clinical cardiologists, and other HCPs who care for patients with peripheral vascular disease.
Dual antiplatelet therapy is used to reduce risks in patients with PAD who undergo lower extremity revascularization, but regimens and practices vary widely. Further, new data on the benefits of dual pathway inhibition by targeting both platelets and thrombin may change approaches for these high-risk, vulnerable patients. Expert discussion and case-based application can help clinicians apply the latest data.
Upon completion of this activity, participants will be able to:
• Interpret the latest data on DOACs in PAD post-revascularization
• Optimize anticoagulant therapy for patients with PAD post-revascularization secondary to patient-specific factors (e.g. type of revascularization, comorbidities, concomitant medications)
• Interpret the latest data on DOACs in PAD post-revascularization
• Optimize anticoagulant therapy for patients with PAD post-revascularization secondary to patient-specific factors (e.g. type of revascularization, comorbidities, concomitant medications)
This activity is sponsored by the Academy for Continued Healthcare Learning.
This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.
Kush Desai, MD, FSIR
Associate Professor of Radiology, Surgery, and Medicine
Division of Interventional Radiology
Northwestern University Feinberg School of Medicine
Chicago, IL
Associate Professor of Radiology, Surgery, and Medicine
Division of Interventional Radiology
Northwestern University Feinberg School of Medicine
Chicago, IL
Anahita Dua, MBChB, MBA, MSc
Vascular Surgeon
Director MGH Vascular Lab
Co-Director of the MGH Vascular Lab
Associate Director of the MGH Wound Care Center
Massachusetts General Hospital
Boston, MA
Christian T. Ruff, MD, MPH
Director, General Cardiology, Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Kush Desai, MD, FSIR
Advisor or Review Panel Member: Boston Scientific Corporation, Cardinal Health, Medtronic, Philips, Tactile Medical
Grant/Research Support Recipient: Boston Scientific Corporation
Consultant: Becton, Dickinson and Company, Boston Scientific Corporation, Cardinal Health, Cook Medical, W. L. Gore & Associates, Medtronic, Philips, Shockwave Medical, Tactile Medical
Speakers' Bureau: Becton, Dickinson and Company, Boston Scientific Corporation, Cook Medical, Medtronic, Tactile Medical
Anahita Dua, MBChB, MBA, MSc
Speaker (Education): MiMedx Group, Inc. and Penumbra, Inc.
Christian T. Ruff, MD, MPH
Consultant (Occasional): Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Alexion (formally Portola)
Grant/Research Support recipient: Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Use of anticoagulants not approved for patients with PAD.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 90 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for up to 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
